All In MedTech

FDA Clearance Tracker · P240012-S005

AeroPace® System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 20, 2026

Approved

Time to decision

28 days

Received Jan 23, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P240012-S005
Device name
AeroPace® System
Applicant location
Exton, PA
Received
Jan 23, 2026
Decided
Feb 20, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P240012

Device type

Device class
Class III

Every decision under product code SDL

FDA's approval statement

As written in FDA's record.

Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240012.

Source documents

Other decisions for Lungpacer Medical USA, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.